Prostate Cancer Diagnostics Solution Market Trends, Challenges and Future Outlook
Prostate Cancer Diagnostics Solution Market Overview 2025-2034
Luton, Bedfordshire, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Global Prostate Cancer Diagnostics Solution Market
The global prostate cancer diagnostics solution market is undergoing a significant transformation, propelled by technological advances, improved patient awareness, and increased healthcare spending. In 2024, the market size is valued at approximately USD 4.18 billion, and it is forecast to reach USD 10.84 billion by 2034, reflecting a strong CAGR of 10%. This growth is primarily fueled by the increasing incidence of prostate cancer globally, driven in part by an aging population, better screening coverage, and enhancements in molecular and imaging-based diagnostics.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/54803/global-prostate-cancer-diagnostics-solution-market#request-a-sample
Prostate cancer remains one of the most prevalent malignancies among men, especially in North America and Europe. While early detection significantly improves prognosis, traditional diagnostic methods such as PSA screening and manual biopsies face criticism for low specificity and overdiagnosis. In response, the market is witnessing a shift toward precision diagnostics using biomarkers, genetic assays, and advanced imaging systems.
Market Growth Drivers The market is influenced by several factors. First, the growing awareness around early screening programs, especially in developed nations, has led to a significant uptick in test volumes. Public health campaigns and evolving guidelines from organizations like the American Urological Association (AUA) and European Association of Urology (EAU) encourage age-appropriate prostate screening. Secondly, technology has improved both the sensitivity and specificity of diagnostic tools. Multiparametric MRI, PSMA-based imaging, liquid biopsy, and AI-assisted pathology have reduced false positives and enabled targeted biopsies.
Healthcare providers are increasingly integrating prostate-specific biomarkers such as PCA3, 4Kscore, SelectMDx, and PHI (Prostate Health Index) into diagnostic workflows. Molecular diagnostics and genomic profiling are also gaining traction for risk stratification and treatment planning. For instance, gene expression panels help differentiate between indolent and aggressive tumors, enabling clinicians to tailor active surveillance or treatment strategies.
Emerging markets in Asia-Pacific, Latin America, and the Middle East are also contributing to market expansion. Improved healthcare infrastructure, greater access to insurance, and the establishment of private diagnostic centers have expanded access to prostate cancer testing beyond urban centers. Governments in countries like China, India, and Brazil are prioritizing cancer screening under national health plans, further accelerating adoption.
Challenges and Constraints Despite promising growth, the prostate cancer diagnostics market faces several challenges. Overdiagnosis and overtreatment remain concerns, particularly in cases where low-risk tumors are detected. Invasive diagnostic procedures, such as transrectal ultrasound (TRUS)-guided biopsies, are associated with discomfort, infection risk, and high costs. Moreover, the accessibility of advanced imaging and molecular testing remains limited in low-income regions.
Regulatory barriers also affect product adoption. Diagnostic test developers must navigate complex approval processes, such as FDA clearance and CE marking, which can delay commercialization. Furthermore, reimbursement coverage for newer tests varies significantly across markets, limiting patient access to cutting-edge solutions in some areas.
Browse full Report - https://exactitudeconsultancy.com/reports/54803/global-prostate-cancer-diagnostics-solution-market
Market Segmentation
By Product Type
Imaging continues to dominate the market owing to its role in tumor localization and staging. This includes multiparametric MRI and PSMA-PET, which are essential for visualizing high-risk tumors. Biomarkers, on the other hand, are rapidly gaining popularity, especially with non-invasive urine and blood-based tests that offer high specificity. Biopsy devices remain essential, particularly for confirmatory diagnosis.
The prostate cancer diagnostics market is segmented into imaging, biomarkers, and biopsy devices.
Product Type
2024 Market Share (%)
2034 Market Value (USD Billion)
CAGR (2025–2034)
Imaging
40%
4.34
9.5%
Biomarkers
35%
3.79
10.2%
Biopsy Devices
25%
2.71
10.8%
By Application
Screening forms the foundation of prostate cancer prevention strategies, accounting for the largest market share. Diagnosis is growing steadily with the adoption of precision-guided biopsy methods. Monitoring applications are increasingly important in active surveillance models and recurrence tracking.
Applications include screening, diagnosis, and monitoring.
Application
2024 Market Share (%)
2034 Market Value (USD Billion)
CAGR (2025–2034)
Screening
45%
4.88
9.8%
Diagnosis
35%
3.79
10.1%
Monitoring
20%
2.17
10.5%
By End User
Hospitals are the largest end users due to their integrated imaging, pathology, and urology departments. Diagnostic laboratories follow closely, with specialized labs offering advanced biomarker panels and gene sequencing. Research institutes contribute to market development through clinical trials and new test validation.
End users encompass hospitals, diagnostic laboratories, and research institutes.
End User
2024 Market Share (%)
2034 Market Value (USD Billion)
CAGR (2025–2034)
Hospitals
50%
5.42
9.9%
Diagnostic Labs
35%
3.79
10.2%
Research Institutes
15%
1.63
10.4%
By Technology
Immunohistochemistry techniques remain widely used due to their cost-effectiveness and accessibility. Molecular diagnostics are growing rapidly, especially with NGS and PCR-based tests enabling more accurate diagnosis. Imaging techniques continue to evolve, with AI-assisted MRI and PSMA scans reshaping early detection.
Technologies include immunohistochemistry, molecular diagnostics, and imaging techniques.
Technology
2024 Market Share (%)
2034 Market Value (USD Billion)
CAGR (2025–2034)
Immunohistochemistry
40%
4.34
9.5%
Molecular Diagnostics
35%
3.79
10.2%
Imaging Techniques
25%
2.71
10.8%
By Distribution Channel
Direct sales dominate the market as most products are sold directly to hospitals and diagnostic centers. Distributors play a key role in reaching secondary markets and mid-sized labs. Online sales are growing quickly, particularly for biomarker kits and reagent supplies, driven by digital procurement platforms.
Distribution channels comprise direct sales, distributors, and online sales.
Distribution Channel
2024 Market Share (%)
2034 Market Value (USD Billion)
CAGR (2025–2034)
Direct Sales
50%
5.42
9.9%
Distributors
30%
3.25
10.3%
Online Sales
20%
2.17
10.5%
Recent Developments
EDX Medical Group has developed an AI-driven prostate cancer supertest that measures over 100 biomarkers using blood and urine samples, achieving 96% accuracy. This test is expected to revolutionize early detection and personalized treatment plans .
Telix Pharmaceuticals received FDA approval for Gozellix, a prostate cancer screening agent designed for PET scanning of PSMA-positive lesions, offering a longer shelf life and enhanced clinical utility .
Key Players
Abbott Laboratories
Siemens Healthineers
Roche Diagnostics
Hologic, Inc.
Myriad Genetics, Inc.
OPKO Health, Inc.
Genomic Health (Exact Sciences Corporation)
MDxHealth
Beckman Coulter, Inc.
Thermo Fisher Scientific Inc.
Market Outlook In the next decade, the prostate cancer diagnostics market is expected to continue evolving toward non-invasive, high-accuracy, and personalized testing paradigms. AI integration will play a pivotal role in radiology and pathology, helping clinicians interpret results faster and more accurately. The convergence of imaging, molecular diagnostics, and clinical decision support tools is paving the way for comprehensive, data-driven diagnostic ecosystems.
Industry players are likely to invest in integrated diagnostic platforms, point-of-care testing innovations, and strategic collaborations with research institutions. Startups and biotech firms are actively exploring liquid biopsy techniques and next-generation sequencing (NGS) for early detection and risk profiling. At the same time, healthcare systems are adopting risk-based screening models to optimize resources and minimize overtreatment.
With increased emphasis on preventive care and patient-centered medicine, prostate cancer diagnostics are poised to become more accessible, reliable, and cost-effective worldwide. Stakeholders that prioritize innovation, regulatory agility, and affordability are expected to capture significant market share in this rapidly expanding field.
This report is also available in the following languages : Japanese (前立腺がん診断ソリューション市場), Korean (전립선암 진단 솔루션 시장), Chinese (前列腺癌诊断解决方案市场), French (Marché des solutions de diagnostic du cancer de la prostate), German (Markt für Prostatakrebsdiagnostiklösungen), and Italian (Mercato delle soluzioni diagnostiche per il cancro alla prostata), etc.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/reports/54803/global-prostate-cancer-diagnostics-solution-market#request-a-sample
Related reports –
Handheld Acoustic Camera Market
The global handheld acoustic camera market is valued at approximately $120 million, reflecting a growing interest in innovative sound visualization technologies. The market is projected to reach around $250 million by 2034, driven by advancements in sensor technology, increased demand from various sectors, and rising awareness of sound management in industrial applications.
https://exactitudeconsultancy.com/reports/54938/global-handheld-acoustic-camera-market
Fully Automatic Autoclave Market
The global fully automatic autoclave market is valued at approximately $1.2 billion in 2024, with a projected growth trajectory that anticipates a market value of around $2.0 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54949/global-fully-automatic-autoclave-market
Veterinary Diagnostic Kits Market
The global veterinary diagnostic kits market is valued at approximately $3.2 billion in 2024 and is projected to reach around $5.4 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54713/global-veterinary-diagnostic-kits-market
Poultry Disease Diagnostic Kit Market
The global poultry disease diagnostic kit market is valued at approximately $920 million in 2024, reflecting a robust growth trajectory driven by increasing poultry production and a rising focus on animal health. By 2034, the market is projected to reach around $1.8 billion, representing significant expansion fueled by advancements in diagnostic technologies and increased awareness of poultry disease management.
https://exactitudeconsultancy.com/reports/54714/global-poultry-disease-diagnostic-kit-market
GIST Mutation Detection Kit Market
The global market for GIST (Gastrointestinal Stromal Tumors) mutation detection kits is valued at approximately $405 million. This market is projected to grow to around $700 million by 2034, reflecting an estimated compound annual growth rate (CAGR) of 6.0%.
https://exactitudeconsultancy.com/reports/54715/global-gist-mutation-detection-kit-market
HPV Genotyping Detection Kit Market
The global HPV genotyping detection kit market is poised for significant growth, with an estimated market value of approximately USD 2.5 billion in 2024. This market is projected to expand to around USD 5.3 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8% during the forecast period of 2025–2034.
https://exactitudeconsultancy.com/reports/54716/global-hpv-genotyping-detection-kit-market
Virus DNA Extraction Kit Market
The global market for virus DNA extraction kits is valued at approximately $1.2 billion in 2024, driven by increasing research activities in genomics and molecular diagnostics. The market is projected to reach about $2.3 billion by 2034, reflecting a robust growth trajectory. This translates to a Compound Annual Growth Rate (CAGR) of around 7.1% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54722/global-virus-dna-extraction-kit-market
SARS-CoV-2 IgM and IgG Antibody Test Kit(Colloidal Gold Method) Market
The global market for SARS-CoV-2 IgM and IgG antibody test kits, particularly those utilizing the colloidal gold method, is valued at approximately $1.2 billion. This market is projected to expand significantly, achieving a value of around $2.8 billion by 2034, driven by increasing demand for rapid and accurate COVID-19 testing solutions. The Compound Annual Growth Rate (CAGR) for this forecast period is estimated at 8.5%.
https://exactitudeconsultancy.com/reports/54723/global-sars-cov-2-igm-and-igg-antibody-test-kit-colloidal-gold-method-market
SARS-CoV-2 Antigen Test Kit Market
The global market for SARS-CoV-2 antigen test kits is projected to reach approximately $4.5 billion in 2024, fueled by continued demand for rapid testing solutions amidst ongoing public health considerations. Over the forecast period from 2025 to 2034, the market is expected to expand significantly, with a projected market value of around $7 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 5.5%, driven by enhanced manufacturing capabilities, technological advancements, and the growing emphasis on home testing solutions.
https://exactitudeconsultancy.com/reports/54724/global-sars-cov-2-antigen-test-kit-market
Plasma Autoclave Market
The global plasma autoclave market is valued at approximately $500 million in 2024, with expectations to reach around $900 million by 2034. This growth trajectory reflects a robust compound annual growth rate (CAGR) of approximately 6% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54726/global-plasma-autoclave-market
Alkaline Bicarbonate Hemodialysis Concentrate Market
The global alkaline bicarbonate hemodialysis concentrate market is valued at approximately $2.8 billion. The market is poised for significant growth, with a projected value of around $4.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.0% during the forecast period of 2025–2034.
https://exactitudeconsultancy.com/reports/54729/global-alkaline-bicarbonate-hemodialysis-concentrate-market
Dental Coloring Liquid Market
The global dental coloring liquid market is valued at approximately $540 million in 2024, with an anticipated growth trajectory that will see it reach around $1.1 billion by 2034. The expected Compound Annual Growth Rate (CAGR) during the forecast period, from 2025 to 2034, is projected to be about 7.3%.
https://exactitudeconsultancy.com/reports/54739/global-dental-coloring-liquid-market
Dental Polishing Paste Market
The global dental polishing paste market is projected to reach approximately $335 million in 2024, with a steady growth trajectory anticipated over the next decade. By 2034, the market value is expected to expand to around $520 million, reflecting a compound annual growth rate (CAGR) of approximately 4.4% during the forecast period of 2025–2034.
https://exactitudeconsultancy.com/reports/54744/global-dental-polishing-paste-market
Dental Acid Etching Agent Market
The global dental acid etching agent market is projected to reach a value of approximately $350 million in 2024, driven by the rising demand for cosmetic dentistry and advancements in dental materials. During the forecast period from 2025 to 2034, the market is anticipated to grow at a CAGR of 6.5%, driven by increasing dental care awareness, technological innovations, and the growing prevalence of dental disorders.
https://exactitudeconsultancy.com/reports/54745/global-dental-acid-etching-agent-market
Root Canal Lubricant Market
The global root canal lubricant market is valued at approximately $180 million in 2024, with projections indicating a robust growth trajectory, reaching an estimated $300 million by 2034. This reflects a Compound Annual Growth Rate (CAGR) of around 5.1% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54748/global-root-canal-lubricant-market
Laryngeal and Tracheal Stents Market
The global laryngeal and tracheal stents market is valued at approximately $450 million. Projections indicate significant growth, with an estimated market value of $1.1 billion by 2034, signaling a robust expansion driven by advancements in medical technology and increasing prevalence of respiratory conditions.
https://exactitudeconsultancy.com/reports/54776/global-laryngeal-and-tracheal-stents-market
Pharmaceutical Grade Medium Chain Triglyceride (MCT) Market
The global pharmaceutical-grade medium chain triglyceride (MCT) market is valued at approximately $550 million, fueled by rising health awareness and the increasing use of MCT in dietary supplements and clinical nutrition. The market is projected to grow significantly, reaching an estimated value of $1.2 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of 8.1% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54781/global-pharmaceutical-grade-medium-chain-triglyceride-mct-market
Hydroxyethyl Starch API Market
The global Hydroxyethyl Starch (HES) API market is estimated at approximately USD 675 million in 2024, with a projected value reaching around USD 1.1 billion by 2034. This growth reflects a robust compound annual growth rate (CAGR) of about 5.1% for the period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54787/global-hydroxyethyl-starch-api-market
Pet Wellness Exams Market
The global pet wellness exams market is expected to reach a value of approximately $3.5 billion in 2024, driven by increasing pet ownership and a growing emphasis on preventive healthcare. The projected market value is estimated to rise to around $5.8 billion by 2034, reflecting a robust demand for wellness services in the pet care sector.
https://exactitudeconsultancy.com/reports/54799/global-pet-wellness-exams-market
Enteric Pathogen Test Kits Market
The global market for enteric pathogen test kits is valued at approximately $1.2 billion in 2024, driven by heightened consumer awareness regarding food safety and stringent regulatory frameworks. The market is projected to reach around $2.3 billion by 2034, reflecting robust growth opportunities in both emerging and established markets.
https://exactitudeconsultancy.com/reports/54808/global-enteric-pathogen-test-kits-market
CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
More Than a Symposium: IOF Builds Momentum Toward the Future of Orthodontics
HONG KONG, June 03, 2025 (GLOBE NEWSWIRE) -- The International Orthodontics Foundation (IOF), in collaboration with the ADA Forsyth Institute (AFI) and the Complutense University of Madrid (UCM), will host the 2025 IOF-ADA Forsyth International Orthodontic Symposium on June 27–28, 2025, at UCM in Madrid, Spain. As the fourth edition in a continuing series, the symposium reflects IOF's enduring commitment to assembling global leaders in orthodontics. While this event brings together more than 30 speakers from over 20 global institutions, it represents more than a two-day academic gathering—it is the latest milestone in IOF's long-term commitment to advancing orthodontics through innovation, global dialogue, and clinical in 2022, IOF believes that innovation is the cornerstone of the future of orthodontics. Its mission is to foster the emergence and application of transformative ideas that can address real-world challenges. As a global platform, IOF brings together early-career and seasoned researchers and clinicians, along with thought leaders across continents to catalyze meaningful progress in orthodontic science and care. Innovation in Focus: A Snapshot of the 2025 SymposiumThe upcoming symposium will explore how emerging technologies are transforming interdisciplinary care. Four key sessions will spotlight advances in 3D biomechanics, aligner systems, the biology of tooth movement, and collaboration across dental specialties. Topics include digital workflow integration, the use of AI in treatment planning, and innovations in orthodontic biomechanics. Unlike traditional conferences, the International Orthodontic Symposium curates its speaker lineup independently, based on scientific merit and clinical relevance. The event also features the 'New Innovator Session,' where IOF Research Grants recipients present their research-in-progress and discuss how novel concepts can translate into practice. As Prof. Conchita Martin, organizing committee member and Professor of Orthodontics and Research Methodology at UCM, states: 'In designing and planning the symposium, our goal was to create an engaging balance between cutting-edge research, practical application, and interactive discussion. This symposium is not only about learning but, in accordance with the IOF mission, providing a platform for researchers and professionals to exchange knowledge and explore new ideas.' Bridging Borders: A Global Stage for Orthodontic InnovationBeyond the symposium, IOF is steadily building a multi-channel platform for knowledge exchange and professional development. Through initiatives such as the IOF Talk, the Clinical Showcase series, IOF supports orthodontic professionals in more than 130 countries and regions, making top-tier orthodontic education more equitable, inclusive, and accessible worldwide. Committed to advancing orthodontic innovation and clinical translation, IOF launched its annual Research Grant program since its inception, attracting 140 applications from across continents and funding 39 outstanding proposals to date. This program prioritizes forward-looking research in fields such as digital orthodontics, biomechanics, gene therapy, and AI applications. By empowering both emerging and established voices in the profession, IOF accelerates the real-world impact of promising ideas — particularly in underserved or rapidly evolving healthcare systems. As one of the field's leading voices, Prof. Theodore Eliades, IOF Science Committee member and Professor and Director of the Orthodontic and Paediatric Dentistry clinics at the University of Zurich, notes: 'What IOF programs offer is an excellent panel of speakers and reviewers, typically made up of scientists, academics, and clinicians—not just users of innovations, but those who generate clinical data and establish validated clinical processes. This list is independently curated by IOF, with the sole objective of pushing the field forward — to explore what orthodontics could look like in the next decade.' What's Next: IOF's Vision for Global Orthodontic InnovationCommitted to strengthening its role as a global hub for orthodontic innovation, IOF will further optimize its initiatives in education, research and collaboration in orthodontics. A major upgrade to IOF's Research Grant program will be unveiled at this year's Symposium, marking a renewed commitment to supporting projects with high application potential and strategic relevance to the profession. In the realm of education, IOF is exploring academic collaborations with leading universities to provide more accessible learning resources for students and young professionals. In parallel, IOF is working to integrate cutting-edge technologies such as AI into training and development, with initiatives like VR/AR-powered learning experiences. Meanwhile, the foundation is also committed to supporting scientific dialogue around complex or controversial topics in orthodontics—such as early treatment—by providing evidence-based guidance and theoretical support for clinical practice. By supporting diverse talent and fostering global exchange, IOF aims to shape a more innovative, inclusive, and patient-centered future for orthodontics. Company: International Orthodontics Foundation Limited Contact Person: Brandon KanEmail: City: Hong Kong A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
Gland Pharma gets USFDA nod for Angiotensin II Acetate Injection, secures 180-day exclusivity
By Markets Desk Published on June 4, 2025, 08:20 IST Gland Pharma Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection, 2.5 mg/mL. The injectable product is bioequivalent and therapeutically equivalent to the reference listed drug GIAPREZA®, developed by La Jolla Pharma LLC. It is indicated for increasing blood pressure in adults suffering from septic or other distributive shock. Importantly, Gland Pharma is the exclusive First-to-File applicant for this product and has secured 180 days of generic drug exclusivity in the U.S. market. According to IQVIA data, US sales of Angiotensin II Acetate Injection stood at approximately USD 58 million for the twelve months ending March 2025, highlighting the commercial opportunity for Gland Pharma. This approval further strengthens Gland Pharma's injectables portfolio and underscores its regulatory and filing capabilities in complex products. Markets Desk at
Yahoo
an hour ago
- Yahoo
AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the 'Best New Technology Solution – Surgical' in the 2025 MedTech Breakthrough Awards. RECELL, FDA-approved for thermal burn wounds and full-thickness skin defects, has treated over 30,000 patients worldwide. RECELL requires significantly less donor skin than traditional grafting, reducing donor-site pain and accelerating recovery. Additional clinical outcomes include fewer procedures, improved functional and aesthetic results, and shorter hospital stays. RECELL GO retains these clinical benefits while enhancing procedural consistency and surgical team coordination, with the physician remaining central throughout the procedure. This design supports adoption in high-volume burn and trauma centers, and enables scalable, cost-efficient deployment across acute wound care settings. 'We appreciate this recognition, which highlights RECELL's advantages in burn and trauma care,' said Jim Corbett, Chief Executive Officer of AVITA Medical. 'By requiring significantly less donor skin than traditional grafting, RECELL reduces donor-site pain, accelerates healing and improves patient outcomes. We remain committed to expanding access and advancing care for patients.' The MedTech Breakthrough Awards honor companies and products shaping healthcare's future. The 2025 program drew over 4,500 nominations globally. In addition to this recognition, Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs of AVITA Medical, was awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category. The Pinnacle Award celebrates companies and individuals who have demonstrated exceptional innovation, leadership, and impact in healthcare. About AVITA Medical, Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System®, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point of care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO™, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'guidance,' 'intend,' 'look forward,' 'may,' 'outlook,' 'project,' 'target,' 'will,' 'would,' and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company's control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the 'Risk Factors' section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties. Authorized for release by the Chief Financial Officer of AVITA Medical, Inc. CONTACT: Investor & Media Contact: Jessica Ekeberg investor@ media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
